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Abstract
Background: Surveillance, Epidemiology, and End Results (SEER) public research database does not include
chemotherapy data due to concerns for incomplete ascertainment. To compensate for perceived lack of data
quality many researchers use SEER-Medicare linked data, limiting studies to persons over age 65. We sought to
determine current SEER ascertainment of chemotherapy receipt in two relatively large SEER registries compared to
patient-reported receipt and to assess patterns of under-ascertainment.
Methods: In 2011–14, we surveyed patients with Stage III colorectal cancer reported to the Georgia and
Metropolitan Detroit SEER registries. 1301/1909 eligible patients responded (68% response rate). Survey responses
regarding treatment and sociodemographic factors were merged with SEER data. We compared patient-reported
chemotherapy receipt with SEER recorded chemotherapy receipt. We estimated multivariable regression models to
assess associations of under-ascertainment in SEER.
Results: Eighty-five percent of patients reported chemotherapy receipt. Among those, 10% (n = 104) were under-
ascertained in SEER (coded as not receiving chemotherapy). In unadjusted analyses, under-ascertainment was more
common for older patients (11.8% age 76+ vs. < 9% for all other ages, p = 0.01) and varied with SEER registries (10.
2% Detroit vs. 6.8% Georgia; p = 0.04). On multivariable analyses, chemotherapy under-ascertainment did not vary
significantly by any patient attributes.
Conclusion: We found a 10% rate of under-ascertainment of adjuvant chemotherapy for resected, stage III
colorectal cancer in two SEER registries. Chemotherapy under-ascertainment did not disproportionately affect any
patient subgroups. Use of SEER data from select registries is an important resource for researchers investigating
contemporary chemotherapy receipt and outcomes.
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Background
Since its inception in 1973, the National Cancer Insti-
tute’s Surveillance, Epidemiology, and End Results
(SEER) program has collected data of critical importance
to cancer epidemiology, policy, and health services re-
search. Today, SEER data cover 30% of the US
population, [1] and have informed over 7000 published
studies. The population-based nature of these data afford
the opportunity to examine cancer care delivery and ex-
plore outcomes in patients beyond those treated at indi-
vidual cancer centers or groups of centers.
Chemotherapy ascertainment in the SEER database has
been considered unreliable, [2, 3] however, limiting its
use as a stand-alone database for one of the most im-
portant aspects of cancer treatment.
Consequently, most population-based studies of
chemotherapy receipt have relied on claims linkages,
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specifically the SEER-Medicare linked dataset, and there-
fore have been restricted to patients aged 65 years and
older. [4–10] While a cancer diagnosis is more common
among the elderly, SEER-Medicare-based studies over-
look those under age 65, resulting in very limited know-
ledge about cancer treatment among the 83% of U.S.
adults who are aged 19–64 years. As well, studies using
SEER-Medicare data are limited by an extended delay in
release relative to SEER data alone because the SEER-
Medicare datasets are only created every other year.
The potential for under-ascertainment of chemother-
apy by SEER registries is real, especially with the increas-
ing use of oral oncolytics and other chemotherapies
administered outside of the hospital setting that can be
difficult for registrars to capture. If under-ascertainment
is prevalent or varies by patient sociodemographic, clin-
ical, or geographic factors, then studies that use SEER
data alone to investigate chemotherapy risk inaccurate
conclusions that could spur unnecessary changes in clin-
ical practice or health policy. If under-ascertainment of
chemotherapy is not a significant problem, however,
SEER data could inform studies that would not be lim-
ited to elderly patients only.
To further explore the current utility of SEER data as
a stand-alone source for population-based studies of
chemotherapy, we compared patient-reported to SEER
Registry-reported receipt of adjuvant chemotherapy
from two diverse population-based registries. We specif-
ically surveyed patients with Stage III colorectal cancer,
the third most common cancer diagnosis among men
and women in the United States. [11] Among patients
with node positive, locally advanced disease, six months
of fluoropyrimidine-based adjuvant chemotherapy is the
standard recommendation following surgical resection
[12–14] as reflected in the National Comprehensive
Cancer Network (NCCN) clinical guidelines. [15] Des-
pite this recommendation, multiple population-based
studies have shown that more than 30% of patients do
not receive adjuvant chemotherapy, with notable racial
and socioeconomic disparities in chemotherapy receipt.
[16–19] In our study we sought to answer the following
questions: 1) How well do select SEER registries ascer-
tain adjuvant chemotherapy receipt in the current era?
and 2) Are there specific demographic subpopulations




As previously detailed, [20] we identified all patients aged
≥18 years who underwent surgical resection for pathologic
stage III colon or rectal cancer between August 1, 2011
and December 31, 2013 and were reported to the Surveil-
lance, Epidemiology, and End Results (SEER) cancer
registries at two representative sites, Metropolitan Detroit,
Michigan and the State of Georgia. Patients were identi-
fied through rapid case ascertainment at the registries util-
izing virtual real-time pathology reports and were eligible
for recruitment starting 4 months after diagnosis, when
chemotherapy should have initiated. [21–24]
Data collection
Our data collection procedures have been detailed previ-
ously. [25] Briefly, we used a modified version of the
Dillman approach for recruitment, including a small in-
centive payment. [26] A research information sheet in
the survey packet included language regarding the study
purpose, risks and benefits of participation, and patient
confidentiality. The return of a completed survey was
considered implied consent to participate in the study.
Survey responses were accepted up to 1 year from the
date of surgery; the last day to accept survey responses
was December 31, 2014. The SEER Registries supple-
mented patient-reported data with clinical information
from the registry and census tract-level area-based mea-
sures of socioeconomic status (SES).
The study protocol was approved by the institutional re-
view boards of the University of Michigan, Wayne State
University, Emory University, the State of Michigan, and
the State of Georgia Department of Public Health.
Measures
We defined the primary dependent variable, under-
ascertainment of chemotherapy, as a Boolean variable
where true was defined by positive patient-reported re-
ceipt of chemotherapy and SEER-coded non-receipt of
chemotherapy. We defined a secondary outcome, over-
ascertainment of chemotherapy, as a Boolean variable
where true was defined as negative patient-reported re-
ceipt of chemotherapy and SEER-coded receipt of
chemotherapy. We measured chemotherapy receipt by
asking: “Did you or are you going to have chemotherapy
to treat your colorectal cancer?” The accuracy of self-
report of cancer treatments, including chemotherapy,
has been validated in previous studies. [27–29] We also
asked about the timing of treatment. Those who re-
ported that they planned to receive chemotherapy but
had yet to start were excluded from analysis (n = 34), so
that the self-reported measure of chemotherapy receipt
in this study was considered positive only for patients
who reported already receiving chemotherapy treatment.
Independent variables included age, gender, marital
status, race, comorbid conditions, insurance status, an-
nual household income, educational attainment, and
area-level SES index (principle component analysis of
area-level high school degree, college degree, and pov-
erty level combined into a composite standardized meas-
ure of the economic environment). Among the 19% of
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cases missing patient-reported annual household in-
come, we performed multiple imputation. Values for
missing income were imputed using sequential multiple
imputation. Five multiply imputed datasets were ana-
lyzed and the results combined to account for additional
uncertainty due to imputation. [30] These results were
compared with model results from the non-imputed
dataset for any meaningful differences.
We assessed primary disease site (colon versus rectum)
via the SEER registry using ICD-O-3 Site codes (colon:
C180–189; rectosigmoid junction/rectum: C199, C209)
and excluding ICD-O-3 histology codes 9050–5, 9140,
and 9590–9992. SEER registries used data from the
American Hospital Association Database to identify the
hospital where the colorectal cancer surgery was per-
formed, and we categorized hospitals based on bed size
collapsed into tertiles. We also ascertained the hospital
nurse:bed ratio (< 1.0, 1.0–1.49, 1.5–1.99, ≥ 2.0), Joint
Commission on Accreditation of Healthcare Organiza-
tions accreditation, American College of Surgeons cancer
program, Accreditation Council for Graduate Medical
Education residency training program, medical school af-
filiation, and Council of Teaching Hospitals status (all yes/
no) but did not include these variables in our final ana-
lyses as they were not significantly associated with under-
ascertainment in either bivariate or multivariable analyses.
To determine the chemotherapy receipt status in
registry data, we used the “RX_SUMM_CHEMO” vari-
able, which indicates any receipt of chemotherapy as
part of initial therapy in SEER (reference SEER Program
Code Manual). SEER defines adjuvant chemotherapy as
postoperative first-course chemotherapy which ends
when the documented treatment plan is completed or at
disease progression, recurrence, or treatment failure. In-
dividuals coded as 00 (none) or 85–87 (chemotherapy
was not administered) were categorized as not receiving
chemotherapy; those assigned codes 01–03 (codes for
chemotherapy with single agent, multiagent and un-
known number of agents) were categorized as receiving
chemotherapy. The 4% who were coded as 88 (planned,
unknown if given) and 99 (unknown if administered)
were excluded from analyses of under-ascertainment.
Analysis
We compared patient-reported and SEER registry-
reported receipt of chemotherapy. We then described
the frequency of chemotherapy under-ascertainment at
each SEER site after grouping patients by clinical and
sociodemographic characteristics, as well as by treat-
ment and hospital characteristics.
Univariate analyses were performed using Pearson’s χ2
tests. We then regressed registry under-ascertainment
on age, sex, race, marital status, number of comorbid
conditions, insurance status, primary tumor site, and
SEER region, adjusting for clustering by hospital. Be-
cause none of the hospital attributes were significantly
associated with under-ascertainment, we omitted these
from the final regression models. We evaluated all first-
order interactions between significant variables; none
were significant except as reported. Survey nonresponse
was significantly greater among older, nonwhite, and
rectal cancer patients. To adjust for this, response
weights were created as inverse probability weights de-
rived from a logistic regression of survey response. The
weights were normalized to equal the observed sample
size and were incorporated in all multivariable models.
[31] Results are presented as unweighted values, with
weighted percentages. All analyses were performed with
SAS 9.4 software (SAS Inc., Cary, North Carolina).
Results
Study sample and response rate
We identified 2168 patients with Stage III colorectal cancer
reported to the SEER registries of Georgia and Detroit,
Michigan using rapid case ascertainment. Among these,
259 (12%) were later determined to be ineligible (non-Stage
III disease, non-colorectal primary, prior cancer diagnosis,
or residing outside the registry area). Of the 1909 eligible
patients included in the final sample, 608 could not
be located or did not return the survey, leaving a
sample of 1301 patients (68% survey response rate).
Of these patients, 48 had missing data in SEER re-
garding chemotherapy receipt. Thus, our analytic
sample was comprised of 1253 patients.
Among the entire analytic sample, 1068 patients self-
reported receipt of adjuvant chemotherapy (85% chemo-
therapy receipt rate). Among patients who self-reported
receipt of chemotherapy, 104 (10%) were coded as not re-
ceiving chemotherapy in SEER (under-ascertained).
Among patients who self-reported non-receipt of chemo-
therapy, 33 (18%) were coded as receiving chemotherapy
in SEER. (Table 1). The sensitivity of SEER to identify pa-
tients who received chemotherapy was 90%; specificity
was 82%. The positive predictive value of SEER was 97%,
and the negative predictive value was 59%.
Table 1 Patient self-report of chemotherapy receipt compared
With SEER registry data











SEER Surveillance, Epidemiology, and End Results
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In univariate analyses, under-ascertainment was
significantly associated with older age (12% age 76+ vs.
< 9% for all other ages, P = 0.01) and in patients living in
Detroit compared with the State of Georgia (11% vs. 7%;
P < 0.04) (Table 2). In multivariable analyses, chemother-
apy under-ascertainment was not associated with any
patient attributes (Table 3). Variable selection techniques
were used to examine models using subsets of the covar-
iates but none of these affected the significance of the
covariates or substantially improved the overall fit of the
model. No meaningful differences were noted in non-
imputed analyses.
Discussion
We have shown a 10% rate of under-ascertainment of
adjuvant chemotherapy among patients with resected,
stage III colorectal cancer in the SEER registries partici-
pating in this study. In multivariable analyses, under-
ascertainment did not vary by patient sociodemographic
factors.
A recent study comparing rates of chemotherapy ascer-
tainment in SEER to those in SEER-Medicare reported a
relatively low sensitivity of chemotherapy ascertainment
in SEER, and cautioned against the use of SEER for studies
of chemotherapy use. [2] However, our study differs from
that study in important ways. Due to the use of SEER-
Medicare data as the criterion for ascertaining receipt of
chemotherapy, the authors did not include patients under
age 65. Furthermore, the study population included only
patients diagnosed between 2000 and 2006, and therefore
does not reflect more recent trends in chemotherapy re-
ceipt. That study, focused on all treatments (radiation,
chemotherapy, and hormone therapy) across all stages of
multiple cancers, did not restrict their analyses to patients
who, according to published guidelines, should have re-
ceived selected therapies. Thus, the authors reported very
low rates of chemotherapy receipt across several cancers,
including colorectal cancer, and reported low sensitivity of
SEER to ascertain chemotherapy receipt for colorectal
cancer when compared with SEER-Medicare (71.4% sensi-
tivity, 95% CI 70.8–72.0).
In contrast, 85% of our study respondents reported re-
ceipt of adjuvant chemotherapy for Stage III colorectal
cancer, a cancer in which clear guidelines for the use of
adjuvant chemotherapy exist. We found high sensitivity of
SEER to identify patients who received chemotherapy
(90% sensitivity) and a high positive predictive value (97%)
, indicating that among those identified in SEER as receiv-
ing chemotherapy, the vast majority also self-reported re-
ceipt of chemotherapy. Our study includes younger
patients and is therefore more representative of the total
population of colorectal cancer patients. Additionally, we
were able to include patients with both Medicare and
non-Medicare health insurance and found no significant
Table 2 Patient characteristics and unadjusted under-
scertainment of chemotherapy by the SEER registry




< 50 219 16.8 3.6
50–64 469 36.1 7.5
65–74 302 23.2 8.4
75+ 311 23.9 11.8
Sex 0.45
Female 601 46.7 8.9
Male 685 53.3 7.7
Marital Status 0.61
Single 545 41.9 8.6
Married 756 58.1 7.8
Comorbid Conditions 0.42
None 319 24.5 6.7
1 398 30.6 9.5
2+ 584 44.9 8.0
Race 0.24
White 889 69.0 7.4
Black 327 25.4 10.5
Other 73 5.7 8.9
Census Tract Composite SES 0.20
High 352 27.1 7.7
Medium 498 38.4 6.9
Low 448 34.5 10.0
Insurance 0.12
None 112 8.8 3.5
Medicaid 51 4.0 11.4
Medicare 578 45.3 9.9
Other 536 42.0 7.0
Primary Disease Site 0.06
Colonc 985 75.7 9.3
Rectum 316 24.3 5.6
Geographic Site 0.04
Detroit 475 36.5 10.2
Georgia 826 63.5 6.8
Hospital Bed Size 0.70
< 300 450 33.8 8.2
300–499 318 24.7 7.0
≥500 533 41.5 8.7
ACS Cancer Program 0.90
Yes 957 75.3 8.2
No 314 24.7 8.0
aPercentage under-ascertained calculated within the weighted sample.
bP values for differences in the proportion of chemotherapy
under-ascertainment by the categories shown. cRectosigmoid primary tumor
sites are included within “Colon”
SES socioeconomic status
ACS American College of Surgeons
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differences in chemotherapy ascertainment by insurance
type. We included patients diagnosed between 2011 and
2013, providing a view into modern use of adjuvant
chemotherapy. In recent years adjuvant chemotherapy for
stage III colon cancer has been one of the most widely ac-
cepted and utilized quality of care measures [22, 32] and
our findings suggest that receipt of adjuvant chemother-
apy has improved significantly over the past decade. Fur-
thermore, we relied upon patient-report of chemotherapy
receipt as the criterion to which we compared SEER ascer-
tainment of chemotherapy, rather than alternate registry
data that could also risk under-ascertainment. Therefore,
we believe that we present a current picture of adjuvant
chemotherapy receipt as reported by patients across the
age spectrum. The relatively low under-ascertainment of
10%, in conjunction with the finding that chemotherapy
under-ascertainment did not disproportionately affect pa-
tient subgroups, suggests that SEER data may be useful in
focused studies of chemotherapy for select cancers and/or
registries.
Because the concern for under-ascertainment of chemo-
therapy in SEER has limited its use as a stand-alone data-
base for population-based studies of chemotherapy, we
focused our study on under-ascertainment as the primary
outcome. To expand upon the understanding of the ac-
curacy of chemotherapy ascertainment in SEER, however,
we looked at possible causes of chemotherapy over-
ascertainment in our study population as a secondary out-
come. We found that most patients who self-reported that
they did not receive chemotherapy were prescribed oral
capecitabine. A few patients started chemotherapy but
stopped after one dose, and it is possible that some pa-
tients had not yet started chemotherapy at the time they
completed the survey, answered “no” to the survey item
regarding receipt of chemotherapy, but then started
chemotherapy shortly afterwards.
There are several ways in which SEER registries can
improve the accuracy of chemotherapy ascertainment.
SEER registries collect chemotherapy data through both
passive and active means where possible. Cancer is a re-
portable disease in all states and the foundation of the
surveillance system in the United States was built upon
hospital reporting. Hospitals directly collect data on pa-
tients receiving chemotherapy at their own facility and
additionally attempt to capture chemotherapy on pa-
tients receiving some diagnostic and treatment services
at their facility who go elsewhere for receipt of medical
oncology care. These data are reported electronically to
SEER Registries on an ongoing basis (passive collection
by SEER). Delivery of chemotherapy outside the hospital
setting is often not actively reported and in those situa-
tions an attempt is made by SEER staff to collect these
data either through remote access to free-standing med-
ical oncology practices, through direct abstracting at the
practice, or through other means of follow-back to those
facilities (active collection by SEER). This is a resource
intensive process, however, that offers enormous chal-
lenges as the number of these practices has increased
over time. Some registries do receive administrative
claims or other electronic files from medical oncology
practices as their means of meeting state reporting re-
quirements and a greater emphasis on collecting these
data through automated means is in place.
Both of the registries included in our study represent a
large proportion of American College of Surgeons Com-
mission on Cancer (CoC) facilities. CoC facilities have
invested sizable effort into trying to capture chemother-
apy administered outside of the hospital to inform qual-
ity measures around standards of care, which may in
part explain the low under-ascertainment. [33, 34] Add-
itionally, Georgia was one of the initial pilot states for
the Rapid Quality Reporting System (RQRS), a web-
based data collection and reporting system that operates
in real time and is enabled through the National Cancer
Table 3 Multivariable logistic regression models of
chemotherapy under-ascertainment
Characteristic Odds Ratio 95% Confidence Interval P
Age, years 0.08

















Hospital Bed Size 0.75
< 100 Ref Ref
300–499 0.86 0.49–1.51
≥500 1.06 0.64–1.76
We present here the covariates of most interest; the multivariable regression
model was adjusted for all covariates (age, sex, marital status, comorbid
conditions, race, composite socioeconomic status, insurance, primary disease
site, geographic site, hospital bed size, and American College of Surgeons
cancer program status). Covariates not shown in the table were not
significantly associated with under-ascertainment of chemotherapy receipt
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Database. Pilot participation in RQRS began in 2008,
and the system has been available to all CoC-accredited
cancer programs since September 2011. [35] RQRS al-
lows expedited data entry of a critical subset of items
specifically relevant to anticipated standard of care treat-
ments, including the receipt of adjuvant chemotherapy
for Stage III colorectal cancer. Additionally, RQRS pro-
vides alerts prompting participating hospitals to review
treatment plans and assure that processes are in place to
foster this care, and to help identify demographic vari-
ables that may have an impact on the successful delivery
of this care. In these ways RQRS has improved both
timely capture and more complete reporting of adjuvant
chemotherapy for select cancers to population-based
registries. [36] Furthermore, studies of the impact of
RQRS have found a significant and sustained increase in
reported receipt of adjuvant chemotherapy for stage III
colorectal cancer among participating sites. [36–38]
Whether this increase in documentation of chemother-
apy receipt also reflects a change in clinical treatment
patterns with actual increased receipt of adjuvant
chemotherapy is unknown. It is plausible that the feed-
back mechanism of RQRS with alerts to participating
hospitals and providers may help to prevent patients
from “falling through the cracks” by functioning as a cue
to provide adjuvant chemotherapy, especially among mi-
nority and underserved populations. [37]
In our study, focused on a specific cancer for which
well-established quality of care metrics exist, we have
shown low rates of under-ascertainment of adjuvant
chemotherapy by SEER registries. Perhaps, rather than
an “all or none” approach to making chemotherapy data
available to researchers, a more nuanced approach could
be considered where specific cancers are individually
evaluated with respect to treatment ascertainment and
cancer-specific datasets are made available. Methods like
these would allow for studies of chemotherapy receipt
among a more complete population of patients, includ-
ing those under age 65 and those with non-Medicare
insurance.
Another benefit to use of SEER registry data is that re-
ceipt of oral chemotherapy agents is recorded. In stage
III colorectal cancer oral chemotherapy, namely capecit-
abine, has become a common component of adjuvant
therapy. [39, 40] While capecitabine is covered under
Medicare Part B because the same drug is available in
injectable form (5-fluoropyrimidine), the ascertainment
of capecitabine receipt using data from the durable med-
ical equipment (DME) claims files available with Part B
data has been shown to be poor. [41] Furthermore, the
majority of oral chemotherapeutic drugs are covered
under Medicare Part D. Historically many researchers
have not included Part D data in their SEER-Medicare
studies of chemotherapy receipt. Because of this, the
SEER capture of chemotherapy receipt is perhaps be-
coming more important as the use of non-intravenous
chemotherapy agents grows and use of SEER data could
provide a more complete picture of receipt of all chemo-
therapy agents.
Our study is subject to several limitations inherent to
survey research. Analyses were limited by the sample of
respondents. We note, however, that the population-
based sampling achieved broad demographic representa-
tion and the 68% response rate is higher than any previ-
ous published cohort of patients with colorectal cancer.
[42] The survey relied on respondent report and was
thus subject to recall bias, but our reliance on patient
reporting permitted individual insights that could not
otherwise be obtained. We mitigated recall bias by
accepting returned surveys only up until one year after
diagnosis. Non-response bias was possible, and those
who responded to the survey may have been more likely
to receive adjuvant chemotherapy than those who did
not respond. It should be noted the results of this study
cannot be directly extrapolated to chemotherapy for
other cancers, which may have different provider distri-
butions and different treatment patterns from colorectal
cancer. Finally, although our sample includes patients
from two large and diverse SEER registries that encom-
pass rural to urban areas as well as Southern and Mid-
western parts of the United States, our data may not be
representative of all SEER registries across the United
States. Further studies of chemotherapy ascertainment
in additional cancers across different SEER registries are
therefore needed.
Conclusions
While SEER data regarding chemotherapy are available
to researchers upon request, it comes with a warning
that it is not appropriate for studies of treatment pat-
terns, disparities in receipt of chemotherapy, or compar-
isons of patient outcomes by receipt of chemotherapy.
In a robust study of a diverse population of patients with
Stage III colorectal cancer using self-reported receipt of
chemotherapy, we have shown a low rate of chemother-
apy under-ascertainment among two large SEER regis-
tries. In addition, no variation in under-ascertainment
was identified by subgroups. Further exploration is
needed to determine if the patterns observed in this
study carry over to other cancers with defined quality
metrics around use of chemotherapy. Use of population-
based registry data for select cancers with high chemo-
therapy ascertainment could be an important resource
to researchers investigating modern day chemotherapy
receipt and outcomes, providing critically important
insight to clinicians and policy makers and informing
patient-centered quality improvement initiatives.
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